CA2300148A1 - Nicotine antagonists for nicotine-responsive neuropsychiatric disorders - Google Patents

Nicotine antagonists for nicotine-responsive neuropsychiatric disorders Download PDF

Info

Publication number
CA2300148A1
CA2300148A1 CA002300148A CA2300148A CA2300148A1 CA 2300148 A1 CA2300148 A1 CA 2300148A1 CA 002300148 A CA002300148 A CA 002300148A CA 2300148 A CA2300148 A CA 2300148A CA 2300148 A1 CA2300148 A1 CA 2300148A1
Authority
CA
Canada
Prior art keywords
nicotine
neuropsychiatric disorders
antagonists
responsive
mecamylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002300148A
Other languages
French (fr)
Other versions
CA2300148C (en
Inventor
Paul Ronald Sanberg
Roland Douglas Shytle
Archie Aaron Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
University Of South Florida
Paul Ronald Sanberg
Roland Douglas Shytle
Archie Aaron Silver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/020689 external-priority patent/WO1999007356A1/en
Application filed by University Of South Florida, Paul Ronald Sanberg, Roland Douglas Shytle, Archie Aaron Silver filed Critical University Of South Florida
Publication of CA2300148A1 publication Critical patent/CA2300148A1/en
Application granted granted Critical
Publication of CA2300148C publication Critical patent/CA2300148C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine.
Combination therapy of mecamylamine with a neuroleptic drug also is disclosed.
The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.
CA002300148A 1997-08-11 1998-08-11 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders Expired - Fee Related CA2300148C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5523497P 1997-08-11 1997-08-11
US60/055,234 1997-08-11
US93536497A 1997-09-22 1997-09-22
US08/935,364 1997-09-22
USPCT/US97/20689 1997-11-07
PCT/US1997/020689 WO1999007356A1 (en) 1997-08-11 1997-11-07 Nicotine antagonists for neuropsychiatric disorders
PCT/US1998/016634 WO1999007378A1 (en) 1997-08-11 1998-08-11 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
CA2300148A1 true CA2300148A1 (en) 1999-02-18
CA2300148C CA2300148C (en) 2009-06-23

Family

ID=27368798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300148A Expired - Fee Related CA2300148C (en) 1997-08-11 1998-08-11 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Country Status (6)

Country Link
JP (1) JP4640888B2 (en)
AU (1) AU8778498A (en)
CA (1) CA2300148C (en)
DK (1) DK1011678T3 (en)
ES (1) ES2299214T3 (en)
WO (1) WO1999007378A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6472799A (en) * 1998-10-16 2000-05-08 Janssen Pharmaceutica N.V. Therapy for improving cognition
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
JP2007516275A (en) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク Therapeutic combinations for cognitive enhancement and psychotic disorders
CA2601509A1 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
US11766429B1 (en) 2020-08-26 2023-09-26 University Of South Florida Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders

Also Published As

Publication number Publication date
ES2299214T3 (en) 2008-05-16
CA2300148C (en) 2009-06-23
DK1011678T3 (en) 2008-05-05
AU8778498A (en) 1999-03-01
WO1999007378A1 (en) 1999-02-18
JP2003524573A (en) 2003-08-19
JP4640888B2 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
EP1405859A4 (en) Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof and intermediate therefor
ZA200200232B (en) Quinuclidine derivatives and their use as muscarinic M3 receptor ligands.
MXPA03001483A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof.
AU2001295481A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
AU2001287694A1 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
PH31335A (en) Naphthalamides as central nervous system agent.
AU2001284021A1 (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
SI0725779T1 (en)
HK1077818A1 (en) Anticholinergic agents, method for producing the same and use thereof as medicaments
AU2003206760A1 (en) Anticholinergic agents, method for producing the same and use thereof as medicaments
HK1092135A1 (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo [3.2.0]heptane is an effective analgesic agent
ZA9911B (en) 2,3-substituted indole compounds as anti-inflammatory and analgesic agents.
MXPA03001510A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof.
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
AU2001235595A1 (en) 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof
HK1040249A1 (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical composition containing said compounds and the use thereof.
CA2300148A1 (en) Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
WO2003039468A3 (en) Antimnemonic therapy for hypermemory syndromes
ZA200110244B (en) Novel xanthone compounds, their preparation and use as medicament.
JO2199B1 (en) Substituted pyrroles
ZA961983B (en) Bicyclic compounds, preparation thereof and use in pharmaceutical compositions.
AU6846300A (en) Use of cyamemazine for cold turkey benzodiazepine treatment
ZA989615B (en) The use of TNF antagonists as drugs for treating septic 39disorders.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180813